Sufeng Qiang

1 Introduction Targeted protein degradation (TPD), particularly via Proteolysis-Targeting Chimeras (PROTACs), has emerged as a revolutionary therapeutic modality. This strategy co-opts the ubiquitin-proteasome system (UPS) by utilizing heterobifunctional molecules to recruit a specific E3 ligase, thereby ubiquitinating and degrading a protein of interest (POI) [1]. Despite its transformative potential, the clinical translation of PROTACs faces significant hurdles.